The young Czech researcher, hepatologist MUDr. Jan Petrášek, Ph.D., has been awarded the prestigious Česká hlava prize for exceptional scientific discovery

1. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009; 360(26): 2758–2769.

2. Mehal WZ, Iredale J, Friedman SL. Scraping fibrosis: Expressway to the core of fibrosis. Nat Med 2011; 17(5): 552–553.

3. Lindor K. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N Engl J Med 2007; 357(15): 1524–1529.

4. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363(14): 1341–1350.

5. Manns MP, Czaja AJ, Gorham JD et al. Diagnosis and management of auto­immune hepatitis. Hepatology 2010; 51(6): 2193–2213.

6. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008; 48(1): 322–335.

7. Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut 2009; 58(5): 704–720.

8. Canbay A, Feldstein AE, Higuchi H et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cyto­kine expression. Hepatology 2003; 38(5): 1188–1198.

9. Seki E, De Minicis S, Osterreicher CH et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13(11): 1324–1332.

10. Seki E, De Minicis S, Gwak GY, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest 2009; 119(7): 1858–1870.

11. Lemmers A, Moreno C, Gustot T et al. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 2009; 49(2): 646–657.

12. Kawai T, Akira S. Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity. Immunity 2011; 34(5): 637–650.

13. Petrasek J, Dolganiuc A, Csak T et al. Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells. Hepatology 2011; 53(2): 649–660.

14. Szabo G, Mandrekar P, Dolganiuc A. Innate immune response and hepatic inflammation. Semin Liver Dis 2007; 27(4): 339–350.

15. Petrasek J, Dolganiuc A, Csak T et al. Type I interferons protect from Toll-like receptor 9-associated liver injury and regulate IL-1 receptor antagonist in mice. Gastro­enterology 2011; 140(2): 697–708.

16. Lucifora J, Durantel D, Testoni B et al. Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology 2010; 51(1): 63–72.

17. Petrasek J, Lippai D, Kodys K et al. IL-1 receptor antagonist treatment attenuates alcoholic liver disease induced by inflammasome-mediated activation of IL-1ß. (Manuscript in preparation).

18. Petrasek J, Hubacek JA, Stickel F et al. Do common genetic variants in endo­toxin signaling pathway contribute to predisposition to alcoholic liver cirrhosis? Clin Chem Lab Med 2009; 47(4): 398–404.

19. O‘Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Am J Gastroenterol 2010; 105(1): 14–32.

20. Imaeda AB, Watanabe A, Sohail MA et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest 2009; 119(2): 305–314.

21. Ma LL, Gao X, Liu L et al. CpG oligodeoxynucleotide triggers the liver inflammatory reaction and abrogates spontaneous tolerance. Liver Transpl 2009; 15(8): 915–923.

22. Dinarello CA. Interleukin-1beta and the autoinflammatory diseases. N Engl J Med 2009; 360(23): 2467–2470.

23. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009; 68(1): 25–32.

24. Comabella M, Julia E, Tintore M et al. Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis. J Neurol 2008; 255(8): 1136–1141.

25. Lazovic J, Basu A, Lin HW et al. Neuro­inflammation and both cytotoxic and vasogenic edema are reduced in interleukin-1 type 1 receptor-deficient mice conferring neuroprotection. Stroke 2005; 36(10): 2226–2231.

26. Couillin I, Vasseur V, Charron S et al. ­IL-1R1/MyD88 signaling is critical for elastase--induced lung inflammation and emphysema. J Immunol 2009; 183(12): 8195–8202.

27. Vandanmagsar B, Youm YH, Ravussin A et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17(2): 179–188.

28. Davoust N, Vuaillat C, Androdias G et al. From bone marrow to microglia: barriers and avenues. Trends Immunol 2008; 29(5): 227–234.

29. Redente EF, Higgins DM, Dwyer-Nield LD et al. Differential polarization of alveolar macrophages and bone marrow-derived monocytes following chemically and pathogen-induced chronic lung inflammation. J Leukoc Biol 2010; 88(1): 159–168.

30. Ito T, Suzuki A, Imai E et al. Bone marrow is a reservoir of repopulating mesangial cells during glomerular remodeling. J Am Soc Nephrol 2001; 12(12): 2625–2635.

31. Semedo P, Palasio CG, Oliveira CD et al. Early modulation of inflammation by mesenchymal stem cell after acute kidney injury. Int Immunopharmacol 2009; 9(6): 677–682.

32. Carnevale D, De Simone R, Minghetti L. Microglia-neuron interaction in inflammatory and degenerative diseases: role of cholinergic and noradrenergic systems. CNS Neurol Disord Drug Targets 2007; 6(6): 388–397.